Observer Reliability of CT Angiography in the assessment of acute ischaemic stroke: Data from the Third International Stroke Trial

Dr Grant Mair[1], Prof Rüdiger von Kummer[2], Dr Alessandro Adami[3], Prof Philip M White[4], Dr Matthew E Adams[5], Prof Bernard Yan[6], Prof Andrew M Demchuk[7], Dr Andrew J Farrall[1], Prof Robin J Sellar[1], Dr Rajesh Ramaswamy[8], Dr Daisy Mollison[1], Dr Elena V Boyd[9], Dr Mark A Rodrigues[8], Dr Karim Samji[8], Dr Andrew J Baird[8], Dr Geoff Cohen[10], Ms Eleni Sakka[1], Mr Jeb Palmer[1], Mr David Perry[10], Prof Richard Lindley[11], Prof Peter AG Sandercock[10], Prof Joanna M Wardlaw[1] and the IST-3 Collaborative Group

1. Division of Neuroimaging Sciences, University of Edinburgh, Western General Hospital, Edinburgh, UK
2. Department of Neuroradiology, Dresden University Stroke Centre, University Hospital, Dresden, Germany
3. Stroke Center, Dept. of Neurology, Sacro Cuore-Don Calabria Hospital, Negrar, Italy
4. Stroke Research Group, 3-4 Claremont Terrace, Newcastle upon Tyne, UK
5. Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK
6. Neurovascular Research Group, Royal Melbourne Hospital, Parkville, Australia
7. Department of Clinical Neurosciences, Calgary Stroke Program, Calgary, Canada
8. Department of Radiology, Royal Infirmary of Edinburgh, Edinburgh, UK
9. Department of Radiology, Northwick Park Hospital, Harrow, UK
10. Division of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, UK
11. Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia

Corresponding Author:
Professor Joanna M Wardlaw
Division of Neuroimaging Sciences
University of Edinburgh
Western General Hospital
Crewe Road
Edinburgh
EH4 2XU
UK

Email: joanna.wardlaw@ed.ac.uk
Phone: +44 131 537 2943
Fax: +44 131 332 5150

Appendix 1

Results of angiography expert panel inter and intra-observer analyses for a range of imaging characteristics assessed on non-contrast CT

Imaging Characteristic	Expert Panel Reliability	
	Inter-observer	Intra-observer
Acute Changes on non-contrast CT		
Ischaemia (y/n and side)	0.66 (0.59-0.75)	0.66 (0.39-0.93)
ASPECTS (10-0)	0.56 (0.47-0.64)	0.64 (0.42-0.82)
IST-3 Ischaemia Score (0-4)	0.59 (0.51-0.68)	0.61 (0.32-0.84)
Ischaemia Depth (0-2)	0.38 (0.24-0.50)	0.54 (0.02-0.90)
Mass Effect (y/n)	0.13 (-0.06-0.30)	0.39 (-0.02-0.80)
Hyperdense Artery (y/n)	0.37 (0.19-0.54)	0.83 (0.58-1.00)
Chronic Changes on non-contrast CT		
Atrophy (0-4)	0.32 (0.20-0.43)	0.46 (0.17-0.70)
Leukoaraiosis (0-4)	0.56 (0.49-0.63)	0.69 (0.34-0.92)
Previous Stroke (y/n)	0.49 (0.32-0.66)	0.47 (0.17-0.78)

Results represent K-alpha (95% confidence interval).
Ischaemia defined as loss of grey-white matter differentiation or parenchymal hypodensity.
ASPECTS = Alberta Stroke Program Early CT Score.

Appendix 2
Sources of funding for the Third International Stroke Trial (IST-3)

Angiography (and perfusion) substudy
Funded by the *National Institutes of Health Research (NIHR) Efficacy and Mechanisms Evaluation Panel* (EME 08-43-52).

Main IST-3 Trial
The start-up phase was supported by a grant from the Stroke Association, UK (TSA 04/99).

The expansion phase was funded by the Health Foundation UK (2268/1282). The scan reading development was funded by Chest, Heart Stroke Scotland (R100/7).

The main phase of the trial was *funded by: UK Medical Research Council (MRC) (grant numbers G0400069 and EME 09-800-15) and managed by NIHR on behalf of the MRC-NIHR partnership;* the Research Council of Norway; Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; the Swedish Heart Lung Fund; The Foundation of Marianne and Marcus Wallenberg, Stockholm County Council; Karolinska Institute Joint ALF-project grants Sweden, the Polish Ministry of Science and Education (grant number 2PO5B10928); the Australian Heart Foundation; Australian *National Health and Medical Research Council* (NHMRC); the Swiss National Research Foundation; the Swiss Heart Foundation; the Foundation for Health and Cardio-/Neurovascular Research, Basel, Switzerland; the Assessorato alla Sanita, Regione dell'Umbria, Italy; and, Danube University, Krems, Austria.

Boehringer-Ingelheim GmbH donated drug and placebo for the 300 patients in the double-blind phase, but thereafter had no role whatsoever in the trial.

The UK Stroke Research Network (SRN study ID 2135) adopted the trial in 01/05/2006, supported the initiation of new UK sites, and in some centres, and, after that date, data collection was undertaken by staff funded by the network or working for associated NHS organisations.

IST-3 gratefully acknowledges the extensive support of the NIHR Stroke Research Network, NHS Research Scotland (NRS), through the Scottish Stroke Research Network, and the National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC).

The central imaging work was undertaken at the Brain Imaging Research Centre (www.bric.ed.ac.uk), a member of the Scottish Imaging Network A Platform for Scientific Excellence (SINAPSE) collaboration (www.sinapse.ac.uk), at the Division of Clinical Neurosciences, University of Edinburgh. SINAPSE is funded by the Scottish Funding Council (SFC) and the Chief Scientist Office of the Scottish Executive (CSO).

Additional support was received from Chest Heart and Stroke Scotland, DesAcc, University of Edinburgh, Danderyd Hospital R&D Department, Karolinska Institutet,

Oslo University Hospital, and the Dalhousie University Internal Medicine Research Fund.

The views are those of the authors and not of the funding sources.